The contract research organization posted revenue of $2.02 billion in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $1.99 billion. Icon PLC expects full-year ...

It has been about a month since the last earnings report for Icon PLC (ICLR). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

2d. ICON plc ICLR is well-poised to grow in the upcoming quarters, driven by its strategic additions. Leveraging AI and technology advancements, ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

A month has gone by since the last earnings report for Icon PLC (ICLR). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

DUBLIN, March 05, 2025--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will provide a live webcast of its Analyst Day ...

Contract research firm ICON Plc said on Wednesday it is partnering with the U.S. government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates. May 10, 2023 ...

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools ...

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...